Zobrazeno 1 - 10
of 536
pro vyhledávání: '"Oliver Gassmann"'
Autor:
Naomi Haefner, Oliver Gassmann
Publikováno v:
Journal of Business Models, Vol 11, Iss 3 (2023)
A conversation with Oliver Gassmann and Naomi Haefner – interviewed by Christian Nielsen
Externí odkaz:
https://doaj.org/article/71c53c8236ab407c874ae8bef4ff7aee
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-14 (2018)
Abstract Historically, research and development (R&D) in the pharmaceutical sector has predominantly been an in-house activity. To enable investments for game changing late-stage assets and to enable better and less costly go/no-go decisions, most co
Externí odkaz:
https://doaj.org/article/d7117fc28f5a4335b36a4ec7b49dc160
Transformation through digital innovation is becoming an imperative for every city. The ‘Smart City'concept promises to solve the most urgent queries of progressive urbanization in the area of mobility, energy, water supply, security, housing depri
Publikováno v:
Industry and Innovation. 29:1108-1139
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1a80889d839cd9785a6394371e0d3f3
https://doi.org/10.1080/13662716.2022.2123307
https://doi.org/10.1080/13662716.2022.2123307
Autor:
Martin A. Bader, Oliver Gassmann
Publikováno v:
Principles of Biomedical Sciences and Industry. :305-315
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0fd6f309d4b08f44eb3e21bde53c4ea
https://doi.org/10.1002/9783527824014.ch16
https://doi.org/10.1002/9783527824014.ch16
Publikováno v:
Drug Discovery Today. 26:2786-2793
Delivering transformative therapies to patients while maintaining growth in the pharmaceutical industry requires an efficient use of research and development (R&D) resources and technologies to develop high-impact new molecular entities (NMEs). Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6187afa20587f414cc3159022456146a
https://doi.org/10.1016/j.drudis.2021.06.015
https://doi.org/10.1016/j.drudis.2021.06.015
Publikováno v:
Drug Discovery Today. 26:2226-2231
We investigated what kind of artificial intelligence (AI) technologies are utilized in pharmaceutical research and development (R&D) and which sources of AI-related competencies can be leveraged by pharmaceutical companies. First, we found that machi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1777581d43e8dcb94ce23a512d6ab94c
https://doi.org/10.1016/j.drudis.2021.04.028
https://doi.org/10.1016/j.drudis.2021.04.028
Autor:
Alexander Schuhmacher, Lucas Wilisch, Oliver Gassmann, Markus Hinder, Andreas Kandelbauer, Michael Kuss
Publikováno v:
Drug Discovery Today. 26:1784-1789
Comparative analysis of the R&D efficiency of 14 leading pharmaceutical companies for the years 1999-2018 shows that there is a close positive correlation between R&D spending and the two investigated R&D output parameters, approved NMEs and the cumu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d932effe99a2f36eaae74e0fe6ea1a6a
https://doi.org/10.1016/j.drudis.2021.05.005
https://doi.org/10.1016/j.drudis.2021.05.005
Publikováno v:
R&D Management. 52:465-483
Without fundamental institutional change, such as a change in laws and regulations, many new technologies cannot achieve their full potential. Efforts to induce institutional change in favor of such technologies are, therefore, increasingly critical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67fee6a2b99d9bd397c87b02f0eb614a
https://doi.org/10.1111/radm.12490
https://doi.org/10.1111/radm.12490
Publikováno v:
Nature Reviews Drug Discovery. 22:177-178
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c5ad2c9d41570bab72ffbc3fa3ee761
https://doi.org/10.1038/d41573-022-00213-z
https://doi.org/10.1038/d41573-022-00213-z